CEAPRO INC - CRPOF STOCK NEWS

Ceapro Inc. reports $5.5 million in sales for the first six months of 2023, lagging behind the $11.7 million from the same period in 2022. Ongoing strategic discussions and planning for uplisting to Nasdaq. Ended the quarter with $11.3 million in cash. Positive results from animal studies on wound healing and tissue regeneration. Encouraging results from research collaboration for potential inhalo-therapeutic. Appointed Mr. Michel Regnier as Senior VP, Technical Operations. Net loss after tax of $1.2 million for the second quarter of 2023. Cash used in operations of $2.2 million for the first six months of 2023. Positive working capital balance of $17.4 million as of June 30, 2023.

Ceapro extends exclusive agreement with Symrise AG for distribution and commercialization of active ingredients in the cosmetic market until 2026.

Ceapro Inc. announces positive results from a pre-clinical study evaluating PGX-processed yeast beta glucan (PGX-YBG) as a potential therapeutic option for interstitial lung diseases (ILD). The study demonstrated that PGX-YBG is respirable and can safely and reliably reprogram macrophages in the lungs of mice. The company is advancing toward a go/no-go milestone for further evaluation of PGX-YBG microparticles in a Phase 1 clinical study. ILD represents a significant unmet medical need and is putting a strain on healthcare systems globally.

Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) announced the appointment of Michel Regnier as Senior Vice President, Technical Operations, effective May 1, 2023. With over 20 years of experience in operations and engineering across the medical device, pharmaceutical, and aerospace industries, Regnier will oversee Ceapro's bioprocessing business unit and the implementation of a pilot scale unit for Pressurized Gas eXpanded (PGX) Technology at the Agri Food Discovery Place in Edmonton.

Regnier aims to enhance product development and support the company's strategic growth as it focuses on commercialization and partnerships for its disruptive technologies. Ceapro continues to strengthen its leadership team and propel its evolution in the biopharmaceutical field.